Amplia uncovers new clue in pancreatic cancer drug trial
Amplia Therapeutics has advanced its cancer drug narmafotinib across four trials, with data suggesting it may work independently of common tumour-causing KRAS gene mutations.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.smh.com.au — the content belongs to Sydney Morning Herald - Home.
